NEW YORK, March 22, 2021 /CNW/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021, MindMed has been added to the FTSE Global Micro-Cap Index (which represents $1.3 trillion in global market cap) and the FTSE Total-Cap index (which represents $54.7 trillion in global market cap). J.R. Rahn…


Previous articlePsychedelic Bulletin: Australian Gov Earmarks $15m for Psychedelic Studies; Otsuka Licences R-ketamine in Japan; DC Initiative Becomes Law
Next articleMindset Pharma Announces $5 Million Bought Deal Financing